ROR1 and neoplasm: Results of the tumor challenge experiments showed that M17 and H17 fusion proteins (carrier + TAA + Fc), regardless of the adjuvant type, inhibited growth of the ROR1+ tumor cells more efficiently than the other fusion proteins (Figure 3B,D).